August, 2024
August 2024
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Maria Babak: How cancer treatment changes as turning from a fatal disease into a manageable one
Aug 13, 2024, 10:24

Maria Babak: How cancer treatment changes as turning from a fatal disease into a manageable one

Maria Babak shared a post on LinkedIn by The Babak Lab:

“I wish cancer is curable in the future.

The Babak Lab offers valuable insights into how cancer treatment is changing as cancer is turning from a fatal disease into a manageable one.

Check it out to learn how we can all contribute to ending cancer.”

Quoting The Babak Lab’s post:

“Beyond Science To Be Curable.

Inspired by Elizabeth Mendes for American Cancer Society.

We’ve gathered a few insights on transforming cancer from a fatal disease to a manageable one.

Explore our latest carousel to discover the groundbreaking advancements and collaborative efforts needed to make this vision a reality.

Ending cancer requires the collective efforts of scientists, doctors, policymakers, and communities.

Explore our carousel to see how we can achieve this together.

Join us in supporting cancer research and innovation.

The future is bright, and with your help we can create a future where cancer is no longer a devastating disease.

Follow American Cancer Society and The Babak Lab for the latest developments in cancer treatment and support research initiatives that bring us closer to a cancer-free world.”

Maria Babak: How cancer treatment changes as turning from a fatal disease into a manageable one

Source: Maria (Masha) Babak/LinkedIn and The Babak Lab/Linkedin

Dr. Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.